SCHEMBL6515670

SCHEMBL6515670

CC(C)(C)OC(=O)CC(=O)N(CCCN1C(=O)c2ccccc2C1=O)c1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.52
KMT2A Q03164 5/20 0.52
MEN1 O00255 4/20 0.52
TSHR P16473 1/20 0.52
NPSR1 Q6W5P4 4/20 0.50
CYP3A4 P08684 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
CYP2D6 P10635 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MAPK1 P28482 1/20 0.49
GAA P10253 3/20 0.49
TDP1 Q9NUW8 3/20 0.48
LMNA P02545 2/20 0.46
KDM4E B2RXH2 2/20 0.41
MAPT P10636 1/20 0.40
MMP2 P08253 1/20 0.40
MMP9 P14780 1/20 0.40
THRB P10828 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12638925 0.73 KMT2A (0.61) ALDH1A1KMT2AMEN1TSHRCYP3A4
SCHEMBL14825114 0.73 ALDH1A1 (0.63) ALDH1A1KMT2AMEN1TSHRNPSR1
SCHEMBL19925980 0.73 MAOB (0.49) ALDH1A1KMT2AMEN1TDP1
SCHEMBL6503782 0.72 KMT2A (0.56) ALDH1A1KMT2AMEN1TSHRSMN1; SMN2
SCHEMBL6306186 0.72 MT-CO2 (0.37) ALDH1A1KMT2AMEN1NPSR1CYP3A4
SCHEMBL15996418 0.72 MAOB (0.51)
SCHEMBL25667511 0.71 HDAC8 (0.58) ALDH1A1KMT2AMEN1CYP3A4CYP2C9
SCHEMBL25797675 0.71 MAOB (0.49)
SCHEMBL11327841 0.71 HPGD (0.58) ALDH1A1KMT2AMEN1TSHRSMN1; SMN2
SCHEMBL9269400 0.71 RAB9A (0.50) ALDH1A1KMT2AMEN1TSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050245563-A1 Chk-1 inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-11-03 US disclosed
WO-2005028474-A2 PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245563-A1 Chk-1 inhibitors CHKA, CHKB, CHEK1 ALDH1A1 4635/4885KMT2A 1919/4885MEN1 1973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.